DOI: 10.4244/EIJ-D-18-00348R

Activation of the coagulation cascade and the role of paravalvular leak in the development of leaflet thrombosis following transcatheter aortic valve replacement

Hashrul N. Rashid, MBBS; James D. Cameron, MBBS, MD; Adam J. Brown*, MB, BChir, PhD

We are grateful for the interest of Deutsch et al in our paper “Bioprosthetic aortic valve leaflet thrombosis detected by multidetector computed tomography is associated with adverse cerebrovascular events: a meta-analysis of observational studies”1.

There remain ongoing concerns regarding the clinical sequelae of developing leaflet thrombosis (LT) following transcatheter aortic valve replacement (TAVR). Observational studies and pooled evidence suggest a significant association between the presence of LT and risk of a cerebrovascular event (CVE)1,2. Furthermore, reduced leaflet motion appeared to have a stronger association with CVE when compared to hypoattenuated leaflet thickening, suggesting CVE might be proportionate to leaflet thrombotic burden. The potential adverse impact of LT on prosthesis longevity is also concerning3, particularly with TAVR being expanded to increasingly younger patient cohorts at lower surgical risk.

Despite these concerns, our knowledge surrounding the pathophysiology of LT following TAVR remains limited. Currently, the development of LT is thought to be multifactorial including, but not limited to, altered fluid haemodynamics, prothrombotic factors and leaflet micro-damage. Prosthesis design may also play a role in the development of LT, with previous evidence demonstrating higher incidence of LT in intra- or sub-annular valves4 and specific valve types5. Paravalvular leak (PVL) has been strongly associated with mortality post TAVR6, and it is possible that there may be a relationship between PVL and risk of LT. PVL leads to higher shear stresses around the prosthesis from regurgitant flow, promoting platelet and coagulation cascade activation7. Malexpanded prostheses may also cause significant PVL8, leading to substantial leaflet stress and micro-filamentous damage9, exacerbating platelet activation10,11. Even so, PVL could be a confounding factor rather than the primary mechanism for LT. Residual PVL immediately post deployment leads to aggressive post-dilatation, precipitating disruption of leaflet material and exposing the thrombogenic collagen fibres12. Moreover, PVL is more likely to occur in heavily calcified annuli13, which is believed to be a prothrombotic environment with low levels of activated factor XI, tissue factor and thrombin generation14,15. Regardless of these considerations, minimising PVL following TAVR remains crucial from a haemodynamic perspective and remains an important marker of procedural success.

Moving forwards, a thorough understanding of the mechanisms that activate the coagulation cascade will be key to understanding the pathophysiology behind LT. Interestingly, a recent study demonstrated that von Willebrand factor levels and closure time with adenosine diphosphate may accurately predict both PVL and mortality post TAVR16, although the study did not specifically assess for the presence of LT. This raises the possibility that the occurrence of LT could be anticipated through periprocedural monitoring of coagulation biomarkers. Alternatively, it is possible that the presence of LT could be safely excluded if the negative predictive value of coagulation markers were found to be high, similar to the role of D-dimer for the exclusion of deep vein thrombosis17. Further prospective trials are now warranted to assess the role of coagulation biomarkers and LT, which will hopefully provide useful screening tools as well as insight into the pathophysiology of this concerning condition.

Funding

A. Brown is supported by a School of Clinical Sciences at Monash Health, Monash University Early Career Practitioner Fellowship award.

Conflict of interest statement

The authors have no conflicts of interest to declare.


References

Volume 14 Number 6
Aug 24, 2018
Volume 14 Number 6
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV13I15A281 Feb 2, 2018
Subclinical leaflet thrombosis – a concern, but also an issue?
Søndergaard L
free

Viewpoint

10.4244/EIJ-D-24-00205 Jul 15, 2024
Subclinical leaflet thrombosis: should we be concerned?
Dangas G and Bay B
free

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA7 Sep 18, 2016
Leaflet motion abnormality after TAVI: genuine threat or much ado about nothing?
Chakravarty T et al
free

10.4244/EIJV8SQA5 Sep 30, 2012
Mechanisms and prediction of aortic regurgitation after TAVI
Petronio AS et al
free
Trending articles
57.8

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
39.45

Clinical research

10.4244/EIJ-D-23-00725 Nov 19, 2023
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al
free
39.45

Original Research

10.4244/EIJ-D-23-00725 Mar 18, 2024
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al
free
36.35

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
35.15

State-of-the-Art

10.4244/EIJ-D-23-00895 Apr 1, 2024
Percutaneous interventions for pulmonary embolism
Finocchiaro S et al
free
28.5

CLINICAL RESEARCH

10.4244/EIJV11I1A6 May 19, 2015
European expert consensus on rotational atherectomy
Barbato E et al
free
22.55

CLINICAL RESEARCH

10.4244/EIJV12I5A93 Aug 5, 2016
Longer pre-hospital delays and higher mortality in women with STEMI: the e-MUST Registry
Benamer H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved